Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer

Published:2011-01 Issue:2 Volume:107 Page:234-239
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:

Author:

Di Lorenzo Giuseppe,Buonerba Carlo,Faiella Adriana,Rescigno Pasquale,Rizzo Mimma,Autorino Riccardo,Perdonà Sisto,Riccardi Nando,Scagliorini Sarah,Scognamiglio Florinda,Masala Daniele,Ferro Matteo,Palmieri Giovannella,Aieta Michele,Marinelli Alfredo,Altieri Vincenzo,De Placido Sabino,Cartenì Giacomo

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2010.09498.x/fullpdf

Reference16 articles.

1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

2. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

3. Castration resistant prostate cancer: from new pathophysiology to new treatment targets;Chi;Eur Urol,2009

4. Management of advanced prostate cancer after first-line chemotherapy;Berthold;J Clin Oncol,2005

5. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience;Ansari;Oncol Rep,2008

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Significant reduction in burden of metastatic disease by intermittent docetaxel therapy in a patient with castration-resistant prostate cancer;International Cancer Conference Journal;2023-12-21

2. Breaking through resistance in mCRPC: Enzalutamide analogues as effective anticancer agents for enhanced male survival;Results in Chemistry;2023-12

3. UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancer;Urologic Oncology: Seminars and Original Investigations;2022-12

4. Tumor microenvironment pH-responsive pentagonal gold prism-based nanoplatform for multimodal imaging and combined therapy of castration-resistant prostate cancer;Acta Biomaterialia;2022-03

5. Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review;Translational Andrology and Urology;2021-10